Nemera launches DuoSpray – Bidose nasal spray
Nemera announces the launch of DuoSpray in September 2026, a bidose nasal spray platform designed to support nasal drug-device combination product development for systemic drug administration.
The nasal route is a non-invasive, needle-free alternative for administering systemic therapies, offering a rapid onset of action and enabling self-administration without healthcare professional intervention.
The launch of DuoSpray reflects Nemera’s strategy to provide pharmaceutical companies with flexible, commercially ready platform solutions that help accelerate the adoption of systemic intranasal therapies.
This new solution complements the commercially available UniSpray platform, strengthening Nemera’s comprehensive offering in systemic nasal drug delivery.
“The launch of DuoSpray is an important step in Nemera’s ambition to become the partner of choice for systemic intranasal drug delivery. By combining complementary liquid platforms with expanding dry powder capabilities, we are building a comprehensive portfolio of intranasal solutions that help pharmaceutical companies bring innovative therapies to patients faster and with reduced development risk. Our goal is not only to provide devices, but to support our customers from early development through successful commercialization,” says Dimitri Grasswill, Vice President, Ear, Nose and Throat (ENT).
Key features
- Ready-to-use, primeless bidose device
- 200 µL delivered as two 100 µL doses
- Visual dose indicator
- One-handed activation with 360° handling
- Compatible with industry-standard primary containers and conventional filling lines
Benefits
- Designed for acute therapy
- Accelerated time-to-mark
- Reduced development risk
- Suitable for innovative drugs, repurposed molecules and generics
- Commercially ready platform
